Diabetes Care, Vol 23, Issue 1 80-83, Copyright © 2000 by American Diabetes Association

ARTICLES

Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study

R Burgos, C Mateo, A Canton, C Hernandez, J Mesa and R Simo
Diabetes Research Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.

OBJECTIVE: To evaluate vitreous levels of IGF-I and its binding proteins IGFBP-1 and IGFBP-3 in patients with proliferative diabetic retinopathy (PDR). Because intravitreal proteins are elevated in patients with PDR due to the disruption of the blood-retinal barrier, we have corrected vitreal IGF-I and IGFBPs by total vitreal proteins to avoid this confounding factor. RESEARCH DESIGN AND METHODS: We compared 21 diabetic patients with proliferative retinopathy (group A) and 13 nondiabetic patients (group B) in whom a vitrectomy was performed. Both groups were matched by age, serum IGF-I, IGFBP-1, and IGFBP-3 levels. Serum and vitreous levels of IGF-I, IGFBP-1, and IGFBP-3 were measured by immunological methods. Vitreal proteins were assessed by turbidimetric method. RESULTS: Vitreal levels of IGF-I were elevated in group A (median 1.35 ng/ml [range 0.3-8.7]) in comparison with group B (median 0.25 ng/ml [range 0-1.38]), P<0.001. After adjusting by vitreal proteins [ratio IGF-I (ng/ml)/protein (mg/ml)], the differences remain significant (P<0.005). Vitreal levels of IGFBP-1 and IGFBP-3 were also elevated in diabetic patients (IGFBP-1: group A, median 1.6 ng/ml [range 0.6-20.7]; group B, median 0.4 ng/ml [range 0.3-1.9], P<0.001. IGFBP-3: group A, median 102.6 ng/ml [range 53.9-350.8]; group B, median 29.0 ng/ml [range 3.2-87.8], P<0.001). However, when the ratio IGFBP/protein was considered, the differences were not significant. CONCLUSIONS: Intraocular synthesis contributes to elevated vitreous concentrations of IGF-I found in PDR. By contrast, unspecific increase of intravitreal proteins is the main factor explaining the elevated vitreous levels of IGFBP-1 and IGFBP-3 found in diabetic patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. B. Bergman, C. J. Moravski, S. R. Edmondson, V. C. Russo, L. A. Bach, J. L. Wilkinson-Berka, and G. A. Werther Expression of the IGF System in Normal and Diabetic Transgenic (mRen-2)27 Rat Eye Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2708 - 2715. [Abstract] [Full Text] [PDF]

				J. L. King and C. Guidry Muller Cell Production of Insulin-like Growth Factor-Binding Proteins In Vitro: Modulation with Phenotype and Growth Factor Stimulation Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4535 - 4542. [Abstract] [Full Text] [PDF]

				C. Guidry, R. Feist, R. Morris, and C. W. Hardwick Changes in IGF Activities in Human Diabetic Vitreous Diabetes, September 1, 2004; 53(9): 2428 - 2435. [Abstract] [Full Text] [PDF]

				J. L. King and C. Guidry Insulin-Like Growth Factor Binding Proteins Modulate Muller Cell Responses to Insulin-Like Growth Factors Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2848 - 2855. [Abstract] [Full Text] [PDF]

				V. Poulaki, A. M. Joussen, N. Mitsiades, C. S. Mitsiades, E. F. Iliaki, and A. P. Adamis Insulin-Like Growth Factor-I Plays a Pathogenetic Role in Diabetic Retinopathy Am. J. Pathol., August 1, 2004; 165(2): 457 - 469. [Abstract] [Full Text] [PDF]

				A. C. Lambooij, K. H. M. van Wely, D. J. Lindenbergh-Kortleve, R. W. A. M. Kuijpers, M. Kliffen, and C. M. Mooy Insulin-like Growth Factor-I and its Receptor in Neovascular Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2192 - 2198. [Abstract] [Full Text] [PDF]

				R. Simo, A. Lecube, L. Sararols, J. Garcia-Arumi, R. M. Segura, R. Casamitjana, and C. Hernandez Deficit of Somatostatin-Like Immunoreactivity in the Vitreous Fluid of Diabetic Patients: Possible role in the development of proliferative diabetic retinopathy Diabetes Care, December 1, 2002; 25(12): 2282 - 2286. [Abstract] [Full Text] [PDF]

				Y. Mitamura, A. Tashimo, Y. Nakamura, H. Tagawa, K. Ohtsuka, Y. Mizue, and J. Nishihira Vitreous Levels of Placenta Growth Factor and Vascular Endothelial Growth Factor in Patients With Proliferative Diabetic Retinopathy Diabetes Care, December 1, 2002; 25(12): 2352 - 2352. [Full Text] [PDF]

				Y. Mitamura, S. Takeuchi, K. Ohtsuka, A. Matsuda, N. Hiraiwa, and M. Kusakabe Tenascin-C Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy Diabetes Care, October 1, 2002; 25(10): 1899 - 1899. [Full Text]

				C. Hernández, R. Burgos, A. Cantón, J. García-Arumí, R. M. Segura, and R. Simó Vitreous Levels of Vascular Cell Adhesion Molecule and Vascular Endothelial Growth Factor in Patients With Proliferative Diabetic Retinopathy: A case-control study Diabetes Care, March 1, 2001; 24(3): 516 - 521. [Abstract] [Full Text]

				R. Simó, R. Burgos, C. Mateo, A. Canton, C. Hernández, and J. Mesa Acknowledgments Diabetes Care, January 1, 2001; 24(1): 177 - 177. [Full Text]